Now showing items 1-5 of 5
Development and evaluation of a solid oral dosage form for an artesunate and mefloquine drug combination
Malaria affects about forty percent of the world’s population. Annually more than 1.5 million fatalities due to malaria occur and parasite resistance to existing antimalarial drugs such as mefloquine has already reached ...
The effect of Pheroid® technology on the bioavailability of artemisone in primates
Malaria is one the world’s most devastating diseases. Several classes of drugs are used to treat malaria. Artemisinin combination therapy is the first line treatment of uncomplicated malaria. The artemisinin derivative, ...
Formulation, characterisation and in vivo efficacy of dapsone and proguanil in trimethylated chitosan microparticles
Malaria is an infectious disease caused by various forms of the Plasmodium parasite. It is responsible for thousands of deaths yearly with 90 % of those deaths being in sub-Saharan Africa, thus making it a disease of global ...
Synthesis and in vitro antimalarial activity of novel chalcone derivatives
Malaria is endemic in 106 countries worldwide. This disease is caused by a parasite from the genus Plasmodium. Of the five species that infect humans, Plasmodium falciparum is the most virulent, with over three billion ...
Radio-labelling as a tool to investigate the absorption and bio-distribution of selected antimalarial drugs
Previous studies have shown that the formulation of an active pharmaceutical ingredient (API) entrapped in the Pheroid® (Pheroid for simplification) delivery system enhances absorption of the API, suppresses its metabolism, ...